期刊文献+

沙利度胺联合小剂量阿糖胞苷及干扰素治疗老年人慢性粒-单核细胞白血病八例 被引量:4

原文传递
导出
摘要 目的 探讨沙利度胺联合小剂量阿糖胞苷、α-2b干扰素(IFN-α-2b)治疗老年人慢性粒-单核细胞白血病(CMML)的临床疗效及安全性.方法 8例患者均于诊断后给予沙利度胺100 mg/d,口服;阿糖胞苷25 mg/m2皮下注射,第1天至第10天,每1个月为1个疗程;IFN-α-2b 50 μg/d,皮下注射,1次/d,治疗6个月后评价血液学缓解率及不良反应.结果 3例患者达到完全缓解,治疗总反应率为62.5%,不良反应轻微.结论 沙利度胺联合小剂量阿糖胞苷、IFN-α-2b治疗老年人CMML可获得较高的反应率,未见明显不良反应.
出处 《白血病.淋巴瘤》 CAS 2014年第3期174-176,共3页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献14

  • 1于亚平,史平,翟勇平,刘海宁,宋萍,李峰,周晓刚,安志明,唐玉梅.地西他滨治疗慢性粒单核细胞白血病及继发皮肤病变一例报告[J].中华肿瘤防治杂志,2011,18(3):227-228. 被引量:5
  • 2Groupe Francais de Cytog6n6tique H6matologique. Chronic myelomonocytic leukemia: single entity or heterogenousdisorder? A prospective multicenter study of 100 patients [J]. Cancer Genet Cytogenet, 1991, 55: 57.
  • 3Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria myelodysplasia[J]. Blood, 2006, 108:419-425.
  • 4姜凤,荆源,王芳婷,林棱,方美云.35例慢性粒-单核细胞白血病细胞形态学特征和染色体核型分析[J].白血病.淋巴瘤,2010,19(1):52-53. 被引量:4
  • 5KrUger N, Zabelina T, Gardiola P, et al. Allogenetic stem cell transplantion for adult chronic myelomonocytic leukemia:a report on behalf of the Chronic Leukemia Working Party the European Group for Bloodand and Marrow Transplantation (EBMT)[J]. Br J I-taematol, 2002, 118: 67-73.
  • 6潘登(综述),李艳(审校).慢性粒单核细胞白血病的诊治进展[J].白血病.淋巴瘤,2012,21(9):569-571. 被引量:7
  • 7Oki Y, Jelinek J, Shen L, et al. Introduction of hypomethylation and molecular response after decitabine therapy in patient with chronic myelomonocytic leukemia [J]. Blood, 2008, 111: 2382-2384.
  • 8梁晓华,林果为,林佩娣,姬美蓉,时俊,唐正贤.慢性粒-单核细胞白血病——附16例分析[J].中华血液学杂志,1996,17(12):626-628. 被引量:10
  • 9Aguayo A, Kantarjian H, Manshouei T, et al. Angiogenesis in acute and chronic leukemia and myelodysplastic syndroms[J]. Blood, 2000, 96: 2240-2245.
  • 10Du GJ, Lin HH, Xu QT, et al. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis[J]. Vasul. Pharmacol, 2005, 43:112-119.

二级参考文献35

  • 1Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myeloid aplastic syndromes. Br J Haematol, 1982, 51: 189.
  • 2Aribi A, Borthakur G, Ravandi F,et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia [J]. Cancer, 2007,109(4):713-717.
  • 3Wijermans P W, Ruter B, Baer M R, et al. Efficacy of decit abine in the treatment of patients with chronic myelomonoeytic leukemia (CMML) [J]. Leuk Res,2008,32(4):587-591.
  • 4Steensma D P, Baer M R, Slack J L, et al. Multicenter Study of Decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastie syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial[J]. J Clin Oncol, 2009, 27(23) : 3842-3848.
  • 5Oki Y, Jelinek J, Shen L, et al. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia [J]. Blood, 2008, 111 ( 4 ) : 2382-2384.
  • 6Onida F, Kantarjian H M, Smith T L, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a ret rospective analysis of 213 patients[J]. Blood, 2002, 99(3) :840- 849.
  • 7Berani M,Wen S, Shen Y,et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M. D. Anderson Prognostic Scoring System[J]. Leuk Lymphoma, 2007, 48(6): 1150-1160.
  • 8Steensma D P, Friday B B. Monocytic skin nodules in chronic myelomonocytic leukemia:Clinical response to decitabine therapy[J]. Leuk Lymphoma, 2007, 48(8):1628-1629.
  • 9Badia L, Alvarez M A, Palau F, et al. Translocation(12; 14) (q13;q32) in myelodysplastic syndrome[J]. Cancer Genet Cyto- genet, 1993, 65(1): 76-78.
  • 10Garcia J S, Jain N, Godley L A. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes[J]. Onco Targets Ther, 2010,3(1):1-13.

共引文献22

同被引文献38

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部